These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16270070)

  • 1. Neurons inflict self-harm.
    Cookson MR
    Nat Med; 2005 Nov; 11(11):1159-61. PubMed ID: 16270070
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine covalently modifies and functionally inactivates parkin.
    LaVoie MJ; Ostaszewski BL; Weihofen A; Schlossmacher MG; Selkoe DJ
    Nat Med; 2005 Nov; 11(11):1214-21. PubMed ID: 16227987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways of neurodegeneration in Parkinson's disease.
    Dawson TM; Dawson VL
    Science; 2003 Oct; 302(5646):819-22. PubMed ID: 14593166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dopaminergic neuronal death in Parkinson's disease: is accumulation of unfolded proteins a cause or effect?].
    Imai Y; Takahashi R
    Tanpakushitsu Kakusan Koso; 2004 May; 49(7 Suppl):1113-7. PubMed ID: 15168542
    [No Abstract]   [Full Text] [Related]  

  • 5. Biomedicine. Parkinson's--divergent causes, convergent mechanisms.
    Greenamyre JT; Hastings TG
    Science; 2004 May; 304(5674):1120-2. PubMed ID: 15155938
    [No Abstract]   [Full Text] [Related]  

  • 6. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation.
    Kitao Y; Imai Y; Ozawa K; Kataoka A; Ikeda T; Soda M; Nakimawa K; Kiyama H; Stern DM; Hori O; Wakamatsu K; Ito S; Itohara S; Takahashi R; Ogawa S
    Hum Mol Genet; 2007 Jan; 16(1):50-60. PubMed ID: 17116640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ubiquitin and Parkinson's disease].
    Tashiro Y; Takahashi R
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1413-7. PubMed ID: 16922410
    [No Abstract]   [Full Text] [Related]  

  • 8. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons.
    Son JH; Kawamata H; Yoo MS; Kim DJ; Lee YK; Kim S; Dawson TM; Zhang H; Sulzer D; Yang L; Beal MF; Degiorgio LA; Chun HS; Baker H; Peng C
    J Neurochem; 2005 Aug; 94(4):1040-53. PubMed ID: 16092945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Sulzer D
    Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation in Parkinson's disease: The future looks bright.
    Paul G; Ahn YH; Li JY; Brundin P
    Adv Exp Med Biol; 2006; 557():221-48. PubMed ID: 16955713
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopaminergic neurons.
    Chinta SJ; Andersen JK
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.
    Wang C; Ko HS; Thomas B; Tsang F; Chew KC; Tay SP; Ho MW; Lim TM; Soong TW; Pletnikova O; Troncoso J; Dawson VL; Dawson TM; Lim KL
    Hum Mol Genet; 2005 Dec; 14(24):3885-97. PubMed ID: 16278233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
    Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
    Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecules that cause or prevent Parkinson's disease.
    Cookson MR
    PLoS Biol; 2004 Nov; 2(11):e401. PubMed ID: 15547643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin.
    Omura T; Kaneko M; Okuma Y; Orba Y; Nagashima K; Takahashi R; Fujitani N; Matsumura S; Hata A; Kubota K; Murahashi K; Uehara T; Nomura Y
    J Neurochem; 2006 Dec; 99(6):1456-69. PubMed ID: 17059562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Views on neurodegeneration as a basis for neuroprotective strategies.
    Riedlerer PF
    Med Sci Monit; 2004 Dec; 10(12):RA287-90. PubMed ID: 15567992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
    Lindholm P; Voutilainen MH; Laurén J; Peränen J; Leppänen VM; Andressoo JO; Lindahl M; Janhunen S; Kalkkinen N; Timmusk T; Tuominen RK; Saarma M
    Nature; 2007 Jul; 448(7149):73-7. PubMed ID: 17611540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NeuN is not a reliable marker of dopamine neurons in rat substantia nigra.
    Cannon JR; Greenamyre JT
    Neurosci Lett; 2009 Oct; 464(1):14-7. PubMed ID: 19682546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural biology of ubiquitin-protein ligases.
    Pavletich NP
    Harvey Lect; 2002-2003; 98():65-102. PubMed ID: 16033158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.